NASDAQ: IRDOpus Genetics Inc Stock
$0.76+0.02 (+2.7%)
Updated Apr 17, 2025
IRD Price
$0.76
Fair Value Price
-$0.67
Market Cap
$34.57M
52 Week Low
$0.65
52 Week High
$2.18
P/E
-0.35x
P/B
5.14x
P/S
2.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.99M
Earnings
-$57.53M
Gross Margin
100%
Operating Margin
-523.4%
Profit Margin
-523.4%
Debt to Equity
1.68
Operating Cash Flow
-$26M
Beta
0.8
Next Earnings
May 8, 2025
Ex-Dividend
N/A
Next Dividend
N/A
IRD Overview
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IRD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
IRD
Ranked#274 of 463
Ranked#274 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important IRD news, forecast changes, insider trades & much more!
IRD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRD ($0.76) is overvalued by 213.62% relative to our estimate of its Fair Value price of -$0.67 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IRD ($0.76) is not significantly undervalued (213.62%) relative to our estimate of its Fair Value price of -$0.67 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IRD due diligence checks available for Premium users.
Valuation
IRD fair value
Fair Value of IRD stock based on Discounted Cash Flow (DCF)
Price
$0.76
Fair Value
-$0.67
Undervalued by
213.62%
IRD ($0.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IRD ($0.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
IRD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.35x
Industry
-177.72x
Market
27.98x
IRD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.14x
Industry
4.05x
IRD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
IRD's financial health
Profit margin
Revenue
$4.3M
Net Income
-$35.1M
Profit Margin
-816.7%
IRD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
IRD's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$36.9M
Liabilities
$11.3M
Debt to equity
1.68
IRD's short-term assets ($36.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRD's short-term assets ($36.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.4M
Investing
$1.2M
Financing
-$83.0k
IRD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
IRD vs Biotech Stocks
Opus Genetics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.